---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-015602"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2026-04-08T23:59:59+00:00"
generated_at: "2026-05-15T06:53:58.886843+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ensysce closes $2M preferred stock financing from prior $20M commitment; conversion price $0.55

## Summary
- Gross proceeds of $2M from second tranche under November 2025 agreement; net ~$1.9M for TAAP and MPAR programs and working capital.
- Conversion price fixed at $0.55 per share; warrants with 100% coverage (18-month and 5-year terms) at $0.55 exercise price.
- Amended Series B preferred stated value from $1,100 to $1,200 per share and issued 8,727,273 warrants.
- CEO Lynn Kirkpatrick states financing reflects continued investor confidence in the company's analgesic programs.
- Financing is part of up to $20M commitment available over 24 months from institutional investor.

## SEC filing metadata
- accession: 0001493152-26-015602
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2026-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315226015602/0001493152-26-015602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315226015602/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-015602
- JSON: https://secwatch.observer/filing/0001493152-26-015602.json
- Plain text: https://secwatch.observer/filing/0001493152-26-015602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.